Is Glimepiride + Metformin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 3 valid registrations of Glimepiride + Metformin, including AMARYL M 2/500 mg film-coated tablet (500,2 mg,mg, Film-coated tablet, SAR 32.00); Amaglime-Met (500,2 mg,mg, Tablet, SAR 19.40); PIRAMYL-MET 2/500 mg Film-coated Tablet (500,2 mg,mg, Film-coated tablet, SAR 26.00).

Active substances

Glimepiride + Metformin

SFDA 4

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
AMARYL M 2/500 mg film-coated tablet	500,2 mg,mg	Film-coated tablet · Oral use	30 Blister	SAR 32.00	NCE · Prescription	Sanofi Arabia Trading Co. Ltd	Valid
Amaglime-Met	500,2 mg,mg	Tablet · Oral use	28 Blister	SAR 19.40	Generic · Prescription	Middle East Pharmaceutical Industries Co Ltd Avalon Pharma	Valid
PIRAMYL-MET 2/500 mg Film-coated Tablet	500,2 mg,mg	Film-coated tablet · Oral use	30 Blister	SAR 26.00	Generic · Prescription	Tabuk Pharmaceutical Manufacturing Company	Valid
AMARYL M 2/500 mg film-coated tablet	2, 500 mg	Film-coated tablet · Oral use	30 Blister	SAR 40.00	NCE · Prescription	SPIMACO ADDWAEIH	Withdrawn by MAH · Not Marketed

Indications — CHI Daman Drug Formulary

DIABETES MELLITUS TYPE 2

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.